P288 Is it safe to discontinue long-term trastuzumab containing therapy after radiological complete response (rCR) in metastatic HER-2 positive breast cancer (MBC)?
- Resource Type
- Article
- Source
- Breast; 2023 Supplement, Vol. 68, pS130-S131, 2p
- Subject
HER2 positive breast cancer TRASTUZUMAB METASTASIS - Language
- ISSN
- 09609776